Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux)

Moreau, P, White, D, Benboubker, L et al. (12 more authors) (2018) Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux). In: Haematologica: the hematology journal. 1st European Myeloma Network Meeting, 19-21 Apr 2018, Turin, Italy. Ferrata Storti Foundation , p. 31.

Metadata

Authors/Creators:	Moreau, P White, D Benboubker, L Cook, G https://orcid.org/0000-0003-0223-3652 Leiba, M Morton, J Ho, PJ Kim, K Takezako, N Trivedi, S Wu, K Casneuf, T Chiu, C Schecter, JM Dimopoulos, MA
Dates:	Published: 18 April 2018
Institution:	The University of Leeds
Depositing User:	Symplectic Publications
Date Deposited:	06 May 2020 12:24
Last Modified:	13 May 2020 10:39
Published Version:	http://www.haematologica.org/content/103/s1/1.full...
Status:	Published
Publisher:	Ferrata Storti Foundation

CORE (COnnecting REpositories)

Updated efficacy and safety analysis of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) for relapsed or refractory multiple myeloma (rrmm; pollux)

Metadata

Download not available

Export

Statistics